Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. Learn More

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Learn More

DMID 13-0053 (Liver Cirrhosis) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how people with cirrhosis respond to a new antibiotic compared to healthy people.
What is the Condition Being Studied?
Liver Cirrhosis

Who Can Participate in the Study?

Adults (age 18-70) with liver cirrhosis and healthy volunteers who:
- Do not smoke or smoke less than 10 cigarettes per day
- Do not have HIV
- Have not donated blood in the past 30 days
- Do not currently abuse drugs or alcohol

Age Group

What is Involved?

If you choose to join the study you will:
- Have a screening visit that will last about 3 hours.
- Be randomized, like the flip of a coin, to one of two groups:
-- One group will receive the study antibiotic OR
-- One group will receive a placebo (an inactive substance)
- Have a 3 day (2 night) inpatient stay in the hospital
- Have 4 follow-up outpatient visits that will last about 1 hour each.  
-- Have blood drawn at each visit.
- Have ECGs, vital signs, and physical exams performed several times throughout the study.  

Study Details

Full Title
A Phase I, Single Dose, Open-label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects with Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Principal Investigator
Protocol Number
IRB: PRO00062544
NCT: NCT02422524
Phase I
Contact the Duke Recruitment Innovation Center